ClinicalTrials.gg
Status unknownNCT06523933Updated Jul 26, 2024

Distribution of Bacteria in OME After Radiotherapy For NPC.

An observational study in Otitis Media Effusion and Nasopharyngeal Carcinoma, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Status unknown at 1 site in China. Open to participants aged 15 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational

The sponsor has not verified this record recently (last verified Jul 2024), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
234
Ages
15 Years to 70 Years
Sex
All
01

Study summary

To observe the prognostic difference of tympanocentesis in different kinds of otitis media effusion.

Read the detailed description

This study is a prospective, observational clinical study to observe the difference in prognosis of tympanocentesis in different kinds of otitis media effusion (OME), especially OME after radiotherapy for nasopharyngeal carcinoma (NPC). A total of 234 patients diagnosed with OME who are given the treatment of tympanocentesis only, including outpatient and inpatient patients, were included in the study. The middle ear effusion collected during the tympanocentesis is sent for bacterial culture. The positive rate of the effusion and the recurrence rate within 24 weeks will be compared in order to figure out whether bacterial infection is an important influencing factor for some kinds of OME in addition to eustachian tube dysfunction, which is acknowledged.

02

Conditions studied

  • Otitis Media Effusion
  • Nasopharyngeal Carcinoma

Keywords

  • Otitis Media Effusion
  • Nasopharyngeal Carcinoma
  • Bacteria
03

In context

Otitis Media with Effusion

85 studies on the registry are indexed under Otitis Media with Effusion; 15 are open to participants now.

This study's planned enrollment of 234 is above the median of 125 across 20 observational studies indexed under Otitis Media with Effusion.

Browse Otitis Media with Effusion studies →

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 477 studies on the registry; 278 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with OME and OME after radiotherapy for NPC, who are given the treatment of tympanostomy only, including outpatient and inpatient patients, were included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients clinical diagnosis of OME or OME after radiotherapy for NPC (Diagnostic criteria: fluid visible in the middle ear and a type B tympanogram).
  • patients volunteered to participate in the study and signed the informed consent

Exclusion criteria

Exclusion Criteria:

  • NPC recurrence or other malignant tumor after radiotherapy.
  • clear diagnosis of Eustachian ostium atresia or nasal obstruction diseases, such as severe deviated nasal septum, choanal atresia, osteoradionecrosis of skull base after radiotherapy, etc.
  • pregnant and lactating women.
  • patients with severe underlying diseases or with severe liver and kidney dysfunction.
  • patients who could not cooperate (including poor hearing and radiation encephalopathy)
  • patients with other middle ear diseases, such as middle ear cholesteatoma, osteoradionecrosis of temporal bone after radiotherapy, etc.
  • severe deglutition disorders
  • cleft palate
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
234 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • ON+

    Patients with OME after NPC with a Positive Result of Bacteria Culture of Middle Ear Effusion.

  • ON-

    Patients with OME after NPC with a Negative Result of Bacteria Culture of Middle Ear Effusion.

  • O+

    Patients with OME with a Positive Result of Bacteria Culture of Middle Ear Effusion.

  • O-

    Patients with OME with a Negative Result of Bacteria Culture of Middle Ear Effusion.

06

What researchers measure

Primary outcomes

  1. Positive Bacterial Culture Rate in Middle Ear Effusion

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Changes in Air Pressure (Tympanogram)

    Tympanogram changed from type B to type A or type C.

    Time frame: Collected at 6, 12, 24 Weeks after Tympanocentesis

  2. Eustachian Tube Dysfunction Questionnaire (ETDQ-7)

    The ETDQ-7 tool is used to assess the symptoms of Otitis Media With Effusion (OME), which consists of seven items with a scale of graduated responses ranging from 1 (No Problem) to 7 (Severe Problem), and 4 would correspond to a Moderate Problem. If the total score is more than 14, it is considered that there is eustachian tube dysfunction. The average post-operative ETDQ-7 score is less than 2.1 or decrease \> 0.5 (minimal clinically important difference=0.5), it is considered that the eustachian tube function is improved.

    Time frame: Collected at 6, 12, 24 Weeks after Tympanocentesis

07

Study locations

1 site
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510120, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06523933
Responsible party
Sponsor
First posted
Jul 26, 2024
Start date
May 12, 2024
Primary completion
Nov 12, 2024 (estimated)
Completion
May 12, 2025 (estimated)
Last update
Jul 26, 2024

Study contacts

Hao Xiong
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion